NAII vs PFE vs VTRS Stock Comparison

Natural Alternatives International, Pfizer and Viatris Prices as of Nov 16, 2026 Peers: Industry group
PFE Pfizer Inc
$28.88 -2.3% 1M +15.2% 1Y
Market cap
$162.19B
P/E
40.2x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
4 wins
VTRS Viatris Inc
$20.74 +11.1% 1M +93.5% 1Y
Market cap
$23.53B
P/E
–
Revenue (TTM)
$14.73B
Div. yield
–
Generic Drugs Healthcare
5 wins

Head to Head

10 decided of 12

Viatris leads on 5 of the 12 questions below (Viatris 5, Pfizer 4, Natural Alternatives International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNAIIPFEVTRSLeader
Larger companyMarket capitalisation $5.65M $162.19B $23.53B PFE
Cheaper on earningsLower P/E, profitable companies only -0.2x 40.2x -38.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 9.8x 7.8x VTRS
Faster revenue growthRevenue growth, trailing twelve months -1.1% +1.3% +4.3% VTRS
More profitableNet margin, trailing twelve months -17.2% 6.3% -4.1% PFE
Better return on capitalReturn on invested capital -32.5% 12.3% 0.0% PFE
Less leveragedLower net debt / EBITDA -0.6x 1.9x 4.1x NAII
Higher dividend yieldTrailing dividend yield 0.00% 0.06% 0.00% –
Better 1-year returnPrice return, last 12 months -69.4% +15.2% +93.5% VTRS
Better 5-year returnAnnualised price return, 5 years -41.3%/yr -10.7%/yr +8.7%/yr VTRS
Less volatileAnnualised volatility, 1 year 65.7% 21.6% 30.9% PFE
Higher overall scoreMean of the five percentile scores vs peers 36/100 62/100 66/100 VTRS

Percentile Scorecard

NAIIPFEVTRS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNAIIPFEVTRS
Valuation 40 #7 of 11 94 #39 of 659 92 #52 of 659
Growth 0 #11 of 11 35 #399 of 617 52 #299 of 617
Profitability 40 #7 of 11 92 #49 of 593 83 #103 of 593
Financial Health 42 #8 of 13 24 #517 of 680 24 #520 of 680
Shareholder Returns 57 #4 of 8 65 #160 of 459 81 #90 of 459
Overall 36 62 66
  • NAII ranked among 13 companies in Pharma Services
  • PFE ranked among 693 companies in Pharmaceuticals and Biotechnology
  • VTRS ranked among 693 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNAIIPFEVTRSSPY
1 month -15.7%-2.3%+11.1% -3.0%
3 months -52.7%+7.5%+27.8% -4.2%
6 months -62.5%+14.0%+25.7% +0.2%
Year to date -72.9%+16.0%+66.6% +8.5%
1 year -69.4%+15.2%+93.5% +10.1%
3 years -84.2%-3.5%+119.5% +64.1%
3 years, per year -46.0%-1.2%+30.0% +18.0%
5 years -93.0%-43.2%+51.9% +58.1%
5 years, per year -41.3%-10.7%+8.7% +9.6%
10 years -92.3%-9.6%-45.3% +239.6%
10 years, per year -22.6%-1.0%-5.9% +13.0%

Risk

MeasureNAIIPFEVTRSSPY
Volatility, 1Y 65.7%21.6%30.9% 13.8%
Downside volatility, 1Y 78.1%21.5%28.6% 14.2%
Beta vs S&P 500, 1Y 0.930.250.64 1.00
Return / volatility, 1Y -1.060.713.03 0.74
Max drawdown, 5Y -93.2%-64.8%-52.9% -25.4%
From 52-week high -79.9%-6.2%-1.5% -5.0%
52-week high $4.83$30.79$21.06 $779.14
52-week low $0.95$23.67$10.19 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNAIIPFEVTRS
P/E now vs peer median -0.3xmedian 34.7x 40.8xmedian 17.1x -39.3xmedian 17.1x
P/S now vs peer median 0.0xmedian 2.5x 2.6xmedian 8.3x 1.6xmedian 8.3x
EV/EBITDA now vs peer median -1.0xmedian 29.1x 8.2xmedian 15.1x 12.6xmedian 15.1x
P/FCF now vs peer median -0.9xmedian 21.0x 14.0xmedian 18.1x 11.3xmedian 18.1x
P/B now vs peer median 0.1xmedian 1.6x 1.8xmedian 2.0x 1.7xmedian 2.0x
PEG now vs peer median 0.00median 1.98 -1.47median 0.43 1.19median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNAIIPFEVTRS
Revenue $132.91M $63.63B $14.73B
Gross profit $5.87M $46.69B $5.20B
Operating income -$21.62M $19.40B -$4.60M
Net income -$22.88M $4.06B -$607.80M
Free cash flow -$6.63M $11.79B $2.11B
R&D – $11.52B $1.00B
EPS (diluted) $-3.77 $0.70 $-0.53
Cash & equivalents $6.49M $1.82B $1.79B
Total debt $17.03M $62.67B $13.32B
Shares (diluted) 6.07M 5.75B 1.15B
Enterprise value -$24.81M $109.55B $16.70B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNAIIPFEVTRS
P/E -0.3x 40.8x -39.3x
P/FCF -0.9x 14.0x 11.3x
P/Operating cash flow -1.6x 11.6x 9.6x
P/S 0.0x 2.6x 1.6x
P/B 0.1x 1.8x 1.7x
P/Tangible book 0.1x 3.8x 39.4x
EV/EBITDA -1.0x 8.2x 12.6x
EV/EBIT -0.8x 11.0x -7,679x
EV/Revenue 0.1x 3.3x 2.4x
EV/FCF -2.5x 18.1x 16.7x
EV/Operating cash flow -4.5x 15.0x 14.2x
PEG (3Y EPS CAGR) 0.00 -1.47 1.19

Growth

14 metrics
MetricNAIIPFEVTRS
Revenue growth (1Y) -1.1% 1.3% 4.3%
Revenue CAGR (3Y) -2.8% -3.2% -1.6%
Gross profit growth (1Y) -48.7% 0.0% 2.3%
Gross profit CAGR (3Y) -28.3% 2.7% -5.3%
Operating income growth (1Y) -230.6% -14.8% 99.8%
Operating income CAGR (3Y) -117.1% 7.4% -26.1%
Net income growth (1Y) -92.6% -58.9% 83.5%
Net income CAGR (3Y) -216.0% -27.2% -32.6%
EPS growth (1Y) -90.4% -59.2% 83.3%
EPS CAGR (3Y) -212.3% -27.7% -32.9%
Operating cash flow growth (1Y) -169.1% 8.4% 25.3%
Operating cash flow CAGR (3Y) -30.6% 5.6% -0.5%
Free cash flow growth (1Y) -757.3% 13.6% 27.1%
Free cash flow CAGR (3Y) -39.8% 13.0% -0.7%

Profitability

14 metrics
MetricNAIIPFEVTRS
Gross margin 4.4% 73.4% 35.3%
EBITDA margin -12.8% 40.7% 19.1%
Operating margin -16.3% 30.5% 0.0%
Pretax margin -17.2% 6.7% -3.6%
Net margin -17.2% 6.3% -4.1%
FCF margin -5.0% 18.5% 14.3%
Operating cash flow margin -2.8% 22.3% 16.9%
Return on equity -45.8% 4.7% -4.3%
Return on assets -18.5% 2.0% -1.7%
Return on invested capital -32.5% 12.3% 0.0%
Return on capital employed -26.7% 11.3% 0.0%
Asset turnover 1.1x 0.3x 0.4x
Cash conversion (OCF / net income) 0.2x 3.5x -4.1x
Stock comp / revenue 0.4% 1.7% 1.2%

Financial Health

11 metrics
MetricNAIIPFEVTRS
Debt / assets 14.9% 30.6% 38.4%
Debt / equity 0.4x 0.7x 1.0x
Net debt / EBITDA -0.6x 1.9x 4.1x
Debt / FCF -2.6x 5.3x 6.3x
Liabilities / assets 58.8% 56.4% 60.5%
Equity / assets 41.2% 43.6% 39.5%
Interest coverage – – 0.0x
Current ratio 1.4x 1.4x 1.6x
Quick ratio 0.5x 0.9x 0.8x
Cash ratio 0.2x 0.4x 0.3x
Altman Z-score 1.19 2.34 1.21

Shareholder Returns

7 metrics
MetricNAIIPFEVTRS
Dividend yield – 6.0% 2.3%
Net buyback yield 1.4% – 0.2%
Shareholder yield 1.4% 6.0% 2.5%
Payout ratio (earnings) – 241.2% –
Payout ratio (FCF) – 83.1% –
Dividend growth (1Y) – 0.9% –
Dividend CAGR (3Y) – 2.2% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNAIIPFEVTRS
Forward P/E – 9.8xFY2026 7.8xFY2026
EPS, next fiscal year – $2.95FY2026 $2.66FY2026
EPS growth, next FY – -8.4%FY2026 +13.2%FY2026
EPS growth, the year after – -5.8% -1.9%
Revenue, next fiscal year – $61.46BFY2026 $15.33BFY2026
Revenue growth, next FY – -1.8%FY2026 +7.2%FY2026
Revenue growth, the year after – +4.0% -4.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNAIIPFEVTRS
Held by institutions 10.5% 66.9% 89.9%
Institutions holding 24 2,842 1,033
Change in shares held, QoQ +6.0% +2.0% +5.6%
Institutions buying 8 1,327 491
Institutions selling 7 1,206 318
Buyers to sellers 1.14 1.10 1.54

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NAIIPFEVTRS
NAII 1.00 0.08 0.06
PFE 0.08 1.00 0.29
VTRS 0.06 0.29 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NAII, PFE and VTRS?

Pfizer (PFE) is the largest by market capitalisation: Natural Alternatives International (NAII) $5.65M, Pfizer (PFE) $162.19B, Viatris (VTRS) $23.53B.

Which company is growing faster?

Viatris (VTRS) grew revenue fastest over the trailing twelve months: Natural Alternatives International (NAII) -1.1%, Pfizer (PFE) +1.3%, Viatris (VTRS) +4.3%.

Which company is more profitable?

Pfizer (PFE) has the highest net margin (Natural Alternatives International (NAII) -17.2%, Pfizer (PFE) 6.3%, Viatris (VTRS) -4.1%). On return on invested capital, Pfizer (PFE) leads (Natural Alternatives International (NAII) -32.5%, Pfizer (PFE) 12.3%, Viatris (VTRS) 0.0%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Natural Alternatives International (NAII) -69.4%, Pfizer (PFE) +15.2%, Viatris (VTRS) +93.5%. Over five years, Viatris (VTRS) compounded fastest (Natural Alternatives International (NAII) -41.3%/yr, Pfizer (PFE) -10.7%/yr, Viatris (VTRS) +8.7%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Natural Alternatives International (NAII) 0.00%, Pfizer (PFE) 0.06%, Viatris (VTRS) 0.00%. Natural Alternatives International (NAII) and Viatris (VTRS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Natural Alternatives International (NAII) 65.7%, Pfizer (PFE) 21.6%, Viatris (VTRS) 30.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NAII, PFE and VTRS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.